Dr Angus McCance
Position:
Clinical Fellow
Research Interests:
Infectious Diseases
Antimicrobial Resistance
Global Health
Tropical Medicine
Background:
Angus completed his medical training at the University of Oxford in 2021, where he also completed a Biomedical Sciences BSc specialising in Infection and Immunity. Whilst an undergraduate he was able to work with the Oxford Cardiovascular Clinical Research Facility and the Oxford Big Data Institute, working on the GRAM Project. He completed the Foundation Program in the South Thames Deanery. Recently, he has returned from two months working as a volunteer medic in Primary Care and Emergency Medicine in rural Guatemala, where he has an ongoing project trying to improve outcomes in the Community Diabetes Clinic.
Key Publications:
2021
Lewandowski AJ, Raman B, Bertagnolli M, Mohamed A, Williamson W, Pelado JL, McCance A, Lapidaire W, Neubauer S, Leeson P. Association of Preterm Birth With Myocardial Fibrosis and Diastolic Dysfunction in Young Adulthood. J Am Coll Cardiol. 2021 Aug 17;78(7):683-692.
2022
Dr Naomi Bulteel
Position:
Consultant Physician
Research Interests:
HIV Therapeutics and Standards of Care
Blood-Borne Virus Infection (HIV/viral hepatitis)
Infectious Diseases
Projects/ grants:
SUPERNOVA
RECOVERY
ISARIC4C
Background:
Naomi Bulteel is a Consultant Physician in Infectious Diseases & General Medicine in Edinburgh, and an Honorary Clinical Senior Lecturer with the University of Edinburgh. She graduated from the University of Edinburgh Medical School in 2008, and completed her Infectious Diseases & General Medicine training in London & South East Scotland. Along the way she read for a PhD in Infection & Immunity at the University of Glasgow, looking at predictors of disease progression and outcome in chronic hepatitis C virus infection. She obtained her Diploma in HIV Medicine in 2019. She was appointed to a consultant position in NHS Lothian in 2023, and is the clinical lead for HIV for the Regional Infectious Diseases Unit.
Key Publications:
2014
2016
2021
All Publications:
2007
Evidence behind the WHO guidelines: hospital care for children: what are the risks of HIV transmission through breastfeeding?
Bulteel N, Henderson P.
2019
2022
2023
Jackie Henderson
RGN
Position:
Research Nurse
Research Interests:
Respiratory Medicine
Infectious Diseases
Background:
Jackie joined the CIRG team in summer of 2023, after years serving within NHS Lothian across both wards and research. Following her involvement in the MABLE study prior to joining CIRG, Jackie continues to apply this interest in her involvement of respiratory infection studies.
Dr Dan Clutterbuck
BSc (Hons) MBChB (Hons) FRCP MRCGP DFSRH
Position:
Consultant in Genitourinary & HIV medicine
Research Interests:
Biomedical HIV and STI prevention in GBMSM
HIV Pre-exposure prophylaxis (PrEP)
Projects/ grants:
Discover: International Randomised Controlled Trial of HIV PrEP (subinvestigator)
Optimising services for people at highest risk of HIV: developing best practice in delivering HIV Pre-Exposure Prophylaxis (PrEP) through evaluation of early implementation across Scotland. (PI: CS Estcourt) Chief Scientist Office Research Grant, HIPS/17/47, 1.6.18-31.5.20, £295,687.
The clinical effectiveness of behaviour change interventions to reduce risky sexual behaviour after a negative HIV test in men who have sex with men (MSM): a systematic review. NIHR HTA Project: 13/77/03, £126,865.
Background:
Dr Dan Clutterbuck qualified in medicine in Liverpool in 1992 and trained in general medicine in Edinburgh followed by general practice in the Scottish Borders. He subsequently completed specialist training in genitourinary & HIV medicine in 2002. He is currently Clinical lead for sexual and reproductive health, NHS Lothian and Clinical lead for HIV at the Chalmers Centre, Edinburgh. He has a particular interest in HIV prevention and the integration of services for MSM into generic sexual health services. He has published research into drug use, sexual behaviour, PreP uptake and HIV testing. He is Current Chair of Scottish Health Protection Network HIV Clinical Leads and is co-author of a number UK guidelines and standards including those on HIV care, PrEP and HIV Testing. He is lead author of BASHH/BHIVA guidelines on safer sex and on sexual health care of men-who-have-sex-with-men (MSM).
Key Publications:
2020
British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020. Palfreeman A, Sullivan A, Rayment M, Waters L, Buckley A,…, Clutterbuck D, …, Peto T. HIV Med. 2020 Dec;21 Suppl 6:1-26. doi: 10.1111/hiv.13015.
2018
Demand for pre-exposure prophylaxis for HIV and the impact on clinical services: Scottish men who have sex with men perspectives. Gilson RI, Clutterbuck DJ, Chen ZE. Int J STD AIDS. 2018 Mar;29(3):273-277. doi: 10.1177/0956462417723817.
2018
Learning from guidelines on the sexual healthcare of men who have sex with men. Clutterbuck D. Int J STD AIDS. 2018 Mar;29(3):298-299. doi: 10.1177/095646241774898.
2018
2016 United Kingdom national guideline on the sexual health care of men who have sex with men. Clutterbuck D, Asboe D, Barber T, Emerson C, Field N, Gibson S, Hughes G, Jones R, Murchie M, Nori AV, Rayment M, Sullivan A. Int J STD AIDS. 2018 Jan 1:956462417746897. doi: 10.1177/0956462417746897.
Dr Iain Page
MBChB, BSc, DTM&H, DipHIV, MRCP (ID), PhD
Position:
Consultant in Infectious Diseases & General Medicine
Research Interests:
Aspergillosis
Infectious Diseases
Projects/ grants:
Principal Investigator: 'Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE)'
Background:
Dr Iain Page is a Consultant in Infectious Diseases & General Medicine at the Western General Hospital in Edinburgh. He has a sub-specialist interest in Fungal Infections and in particular Chronic Pulmonary Aspergillosis (CPA) and is establishing a clinical service for CPA patients in collaboration with respiratory physician colleagues. He is also engaged in COVID-19 research and is Principal Investigator for the Valneva COVID vaccine trial and an Investigator for the Oxford vaccine trial and RECOVERY therapeutics trials in Edinburgh.
He completed medical school and junior doctor training in Edinburgh. From 2007 he combined specialist training in Infectious Diseases in Manchester with several years teaching and leading research projects in Malawi and Uganda. He completed his PhD on Chronic Pulmonary Aspergillosis in 2015 and was subsequently an Academic Clinical Lecturer at the UK National Aspergillosis Centre in Manchester, before returning to Edinburgh in 2020. He is secretary of CPANet, the European clinical network for CPA research.
Key Publications:
2019
Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Page ID, Byanyima R, Hosmane S, Onyachi N, Opira C, Richardson M, Sawyer R, Sharman A, Denning DW. European Respiratory Journal. 2019. DOI: 10.1183/13993003.01184-2018
2018
Case Definition of Chronic Pulmonary Aspergillosis in Resource-ConstrainedSettings. Denning DW, Page ID, Chakaya J, Chakrabarti A, …27 others… Cole DC, Haileyesus G Emerging Infectious Diseases. 2018 Aug;24(8). doi: 10.3201/eid2408.171312.
2017
A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. Godet C … Page ID, Seidel D, Salzer H. Journal of Antimicrobial Chemotherapy. 2017. doi:10.1093/jac/dkx390.
2016
Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). Page I, Richardson M, Denning DW. Journal of Infection. 2016;72(2):240-9.
2015
International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigates. Verweij P… Page I et.al. Drug Resistance Updates. 2015;21-22:30-40. doi: 10.1016/j.drup.2015.08.001
All Publications:
2018
Role of serological tests in the diagnosis of mold infections.. Richardson M & Page ID. Current Fungal Infection Reports 2018. Sept 5. https://doi.org/10.1007/s12281-018-0321-1.
Treatment of chronic pulmonary aspergillosis: current standards and future perspectives. Alastruey-Izquierdo A, … Page ID, Salzer HJF et al on behalf of CPAnet. Respiration. 2018 doi:10.1159/000489474
Siemens Immulite Aspergillus-specific IgG assay for chronic pulmonary aspergillosis diagnosis. Page ID, Richardson M & Denning DW. . Medical Mycology. 2018. doi:10.1093/mmy/myy024.
Receiver operating characteristic curve analysis of four Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. Page ID, Baxter C, Hennequin C, Richardson M, van Hoeyveld E, van Toorenenbergen A, Denning D. Diagnostic Microbiology and Infectious Diseases. 2018. https:doi.org/10.1016/j.diagmicrobio.2018.01.001.
2017
Elevated Aspergillus-specific antibody levels among HIV-infected Ugandans with pulmonary tuberculosis. Kwizera R, Ratanshi R, Page I et al. BMC Pulmonary Medicine. 2017(17):149.
Aspergillus serology – have we arrived yet? Richardson MD & Page ID. Medical Mycology. 2017 1;55(1):48-55 doi: 10.1093/mmy/myw116.
2016
Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis. Muldoon, EG, Sharman A, Page I, Bishop P, Denning DW. BMC Pulmonary Medicine. 2016.
2015
Antibody testing in aspergillosis – quo vadis? Page ID, Richardson M, Denning D. Medical Mycology. 2015. 53(5): 417-439. doi:10.1093/mmy/myv020
2013
Screening HIV infected adults in Malawi for anaemia: need for a new haemoglobin threshold to determine eligibility for antiretroviral therapy. Page I, McKew S, Kudzala A, Fullwood C, van Oosterhout J and Bates I. International Journal of STD & AIDS. 2013; 24(6): 449-53.
2011
The impact of new National HIV Testing Guidelines at a District General Hospital in an area of high HIV sero-prevalence. Page I, Phillips M, Flegg P, Palmer R. Journal of the Royal College of Physicians of Edinburgh. 2011, 41:9-12.
Implementing the Surviving Sepsis Guidelines in a District General Hospital. Page I, Hardy GD, Fairfield J, Orr D, Nichani R. Journal of the Royal College of Physicians of Edinburgh 2011; 41:309-15.
Dr Oliver Koch
DPhil FRCP DipTravMed FFTM
Position:
Consultant in Infectious Diseases & Honorary Senior Clinical Lecturer
Research Interests:
COVID-19
Travel Medicine
Tropical Medicine
Projects/Grants
ISARIC4C – Coronavirus Clinical Characterisation Consortium
RECOVERY – International clinical trial aiming to identify treatments that may be beneficial for adults hospitalised with confirmed COVID-19.
DEFINE – Phase 2 interventional trial is looking at various drug treatments in the treatment of COVID-19
HEAL-COVID – clinical trial to compare different treatments to determine whether they can improve the longer-term outcomes for patients who have been hospitalised due to COVID-19
Background:
After graduating from the University of Witten / Herdecke Medical School (Germany) in 1999 Dr Oliver Koch undertook research focussed on genetic susceptibility to malaria and malaria parasite genetics at the University of Oxford. He completed his clinical training in Nottingham, London and Oxford with periods overseas in Thailand and Cambodia as part of a clinical lectureship. Since 2013 he has worked as a clinical consultant in Infectious Diseases for NHS Lothian. He has a particular interest in tuberculosis, travel & tropical medicine. He is the clinical lead for high consequence infectious diseases and travel medicine for the Regional Infectious Diseases Unit, Edinburgh.
Publications:
2023
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis (DEFINE): A Phase Ib/IIa Randomised Controlled Trial. Gaughan EE., Quinn TM., Mills A., Bruce AM., Antonelli J., MacKinnon A., Alanis V., Li F., O’Connor R., Boz C., Mills R., Emanuel P., Burgess M., Rinaldi G., Valanciute A., Mills B., Scholefield E., Hardisty G., Gwyer Findlay E., Parker RA., Norrie J., Dear JW., Akram AR., Koch O., et al. Am J Respir Crit Care Med. 207(2):138-149. doi: 10.1164/rccm.202203-0477OC.
2022
Performance status: A key factor in predicting mortality in the first wave of COVID-19 in South-East Scotland. Mutch CP., Ross DA., Bularga A., Cave RNR., Chase-Topping ME., Anand A., Mills NL., Koch O., Mackintosh CL., Perry MR.; DataLocj COVID-19 Collaborative. J R Coll Physicians Edinb. 52(3):204-212. doi: 10.1177/14782715221120137.
Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. Quinn TM., Gaughan EE., Bruce A., Antonelli J., O’Connor R., Li F., McNamara S., Koch O., et al. Ebiomedicine 76:103856.
2021
Diagnostic performance of the combined nasal and throat swab in patients admitted to hospital with suspected COVID-19. Lee K.K., Doudesis D., Ross D.A., Bularga A… Koch O… Mills N.L. Bmc Infect Dis 21, 318. https://doi.org/10.1186/s12879-021-05976-1
2020
Coronavirus disease (COVID-19) Community Testing Team in Scotland: A 14-day review, 6 to 20 February 2020. Mark, K., Steel, K., Stevenson, J., Evans, C., McCormick, D., Willocks, L., McCallum, A., Jones, L., Johannessen, I., Templeton, K., Koch, O., Mackintosh, C. European Communicable Disease Bulletin, 2020, 25(12). http://doi.org/10.2807/1560-7917.ES.2020.25.12.2000217
Two cases of imported respiratory diphtheria in Edinburgh, Scotland, October 2019. Li, L., Ross, D., Hill, K., Clifford, S.,… Koch, O., …Stevenson, J. Epidemiology and Infection, 2020, 1-11. http://doi.org/10.1017/S0950268820001028
The index case of SARS-CoV-2 in Scotland. Hill, K. J., Russell, C. D., Clifford, S., Templeton, K., …Koch, O., …Sutherland, R. K. The Journal of Infection. 2020. http://doi.org/10.1016/j.jinf.2020.03.022
Interferon-gamma polymorphisms and risk of iron deficiency and anaemia in Gambian children. Abuga, K. M., Rockett, K. A., Muriuki, J. M., Koch, O., …Atkinson, SH. Wellcome Open Research, 2020. 5, 40. http://doi.org/10.12688/wellcomeopenres.15750.1
Case report: meningitis as a presenting feature of anti-NMDA receptor encephalitis. Stavrou, M., Yeo, J. M., Slater, A. D., Koch, O., Irani, S., & Foley, P. BMC Infectious Diseases, 2020. (1), 21–4. http://doi.org/10.1186/s12879-020-4761-1
Drive-through testing in COVID-19: experience from NHS Lothian. Hill, K., Campbell, R., Mutch, C., Koch, O., & Mackintosh, C. Clinical Medicine (London, England), 20(3), 290–291. http://doi.org/10.7861/clinmed.2020-0160
2019
Successful reintroduction of tumour necrosis factor-alpha inhibition after treatment of disseminated Lyme borreliosis. Bulteel, N. S., Russell, C. D., Perry, M. R., & Koch, O. The Journal of the Royal College of Physicians of Edinburgh, 2019. 49(2), 122–124. http://doi.org/10.4997/JRCPE.2019.207
2016
Diagnosis and features of hospital-acquired pneumonia: a retrospective cohort study. Russell, C. D., Koch, O., Laurenson, I. F., O’Shea, D. T., Sutherland, R., & Mackintosh, C. L. Journal of Hospital Infection, 2016. 92(3),273–279.
Staphylococcus caprae native mitral valve infective endocarditis. Kwok TC, Poyner J, Olson E, Henriksen P, Koch O. JMM Case Rep, 2016. 3(5):e005065. Doi 10.1099/jmmcr.0.005065
2015
Rapidly growing mycobacteria as emerging pathogens in bloodstream and device-related infection: a case of pacemaker infection with Mycobacterium neoaurum. Hayton E-J R, Koch O, Scarborough M, Sabharwal N, Drobniewski F, Bowler ICJW. Journal of Medical Microbiology Case Reports. 2015. 2(3). http://doi.org/doi:10.1099/jmmcr.0.000054
2013
Multiple populations of artemisinin‐resistant Plasmodium falciparum in Cambodia. Miotto O, Almagro‐Garcia J, Manske M, MacInnis B… Koch, O., …Kwiatkowski DP. Nat Genet. 2013. Jun;45(6):648-55.
2012
Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples. Venkatesan M, Amaratunga C, Campino S, Auburn S, …Koch, O., …Plowe CV. Malaria Journal. 2012. 11:41.
2008
Does using self-completed sexual history questionnaires in HIV-positive men who have sex with men affect clinical outcomes? Koch O, De Silva S, Edwards S, Peake T, …Benn P. International Journal of STD & AIDS. 2008. 19(3): 203-205.
2006
Implications of inter-population linkage disequilibrium patterns on the approach to a disease association study in the human MHC class III. Hanchard N, Diakite M, Koch O, Keating B, …Rockett K. Immunogenetics. 2006. 58(5-6): 465-70.
Context-specific functional effects of IFNGR1 promoter polymorphism. Koch O, Kwiatkowski D and Udalova I. Human Molecular Genetics, 2006. 15(9):1475-1481.
An investigation of transmission ratio distortion in the central region of the human MHC. Hanchard N, Rockett K, Udalova I, Wilson J, … Koch, O., …Kwiatkowski D. Genes Immun. 2006. Jan;7(1):51-8.
2005
Investigation of malaria susceptibility determinants in the IFNG/IL26/IL22 genomic region. Koch O, Rockett K, Jallow M, Pinder M, Sisay-Joof F, Kwiatkowski D. Genes Immun. 2005 Jun;6(4):312-8.
Risk of trachomatous scarring and trichiasis in Gambians varies with SNP haplotypes at the interferon-gamma and interleukin-10 loci. Natividad A, Wilson J, Koch O, Holland MJ, …Bailey RL. Genes Immun. 2005 Jun;6(4):332-40.
2004
No association between interferon-gamma receptor-1 gene polymorphism and pulmonary tuberculosis in a Gambian population sample. Awomoyi A, Nejentsev S, Richardson A, Hull J, Koch O,…Newport MJ. Thorax. 2004. 59:291-294.
2001
IFNGR1 Gene Promoter Polymorphisms and Susceptibility to Cerebral Malaria. Koch O, Awomoyi A., Usen S, Muminatou J,…Kwiatkowski D Journal of Infectious Diseases. 2001. 185:1684-7.
Research Outputs as Part of the ISARIC4c Consortium: https://isaric4c.net/outputs/
Research Outputs as Part of the RECOVERY Collaborative Group: https://www.recoverytrial.net/results
Dr Claire Mackintosh
BsC (hons) MBChB FRCP DTM&H PhD
Position:
Clinical Director RIDU, Consultant Infectious Disease Physician, Honorary Senior Lecturer University of Edinburgh
Research Interests:
Health Equity
Infectious Diseases
Projects/ grants:
COVID-19 DataLoch collaboration investigating impact of deprivation
Background:
Key Publications:
2020
Coronavirus disease (COVID-19) Community Testing Team in Scotland: A 14-day review, 6 to 20 February 2020. Mark K, Steel K, Stevenson J, Evans C, McCormick D, Willocks L, McCallum A, Jones L, Johannessen I, Templeton K, Koch O, Mackintosh C. Euro Surveill.2020 Mar;25(12):2000217. doi: 10.2807/1560-7917.ES.2020.25.12.2000217.
Inequitable access to an outpatient parenteral antimicrobial therapy service: linked cross-sectional study. Sumpter C, Russell CD, Mackintosh C. Int J Equity Health. 2020 Sep 1;19(1):150. doi: 10.1186/s12939-020-01261-w.
2011
Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. Mackintosh CL, White HA, Seaton RA. J Antimicrob Chemother. 2011 Feb;66(2):408-15. doi: 10.1093/jac/dkq445.
2008
Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Mackintosh CL, Mwangi T, Kinyanjui SM, Mosobo M, Pinches R, Williams TN, Newbold CI, Marsh K. Int J Parasitol. 2008 Oct;38(12):1445-54. doi: 10.1016/j.ijpara.2008.03.009
All Publications:
2021
Equity for excellence in academic institutions: a manifesto for change. Wedekind L, Noe A, Mokaya J, Tamandjou C, Kapulu M,…Mackintosh CL,… Matthews PC. Wellcome Open Research 2021, 6:142
Diagnostic performance of the combined nasal and throat swab in patients admitted to hospital with suspected COVID-19. Lee KK, Doudesis D, Ross DA, Bularga A, MacKintosh CL, Koch O, Johannessen I, Templeton K, Jenks S, Chapman AR, Shah ASV, Anand A, Perry MR, Mills NL; DataLoch COVID-19 Collaboration. BMC Infect Dis. 2021 Apr 6;21(1):318. doi: 10.1186/s12879-021-05976-1.
As Part of the RECOVERY Collaborative Group:
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7.
2020
The index case of SARS-CoV-2 in Scotland. Hill KJ, Russell CD, Clifford S, Templeton K, Mackintosh CL, Koch O, Sutherland RK. J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.022.
Drive-through testing in COVID-19: experience from NHS Lothian. Hill K, Campbell R, Mutch C, Koch O, Mackintosh C. Clin Med (Lond). 2020 May;20(3):290-291. doi: 10.7861/clinmed.2020-0160
Coronavirus disease (COVID-19) Community Testing Team in Scotland: A 14-day review, 6 to 20 February 2020. Mark K, Steel K, Stevenson J, Evans C, McCormick D, Willocks L, McCallum A, Jones L, Johannessen I, Templeton K, Koch O, Mackintosh C. Euro Surveill. 2020 Mar;25(12):2000217. doi:10.2807/1560-7917.ES.2020.25.12.2000217
Inequitable access to an outpatient parenteral antimicrobial therapy service: linked cross-sectional study. Sumpter C, Russell CD, Mackintosh C. Int J Equity Health. 2020 Sep 1;19(1):150. doi: 10.1186/s12939-020-01261-w.
A Subgroup of Patients With Hospital-acquired Pneumonia Do Not Require Broad-spectrum Gram-negative Antimicrobial Coverage. Russell CD, Whittaker E, Dee DP, Farquhar E, Saenz de Villaverde A, Evans MH, Laurenson IF, Mackintosh CL, Cevik M. Clin Infect Dis. 2020 Dec 17;71(10):e710-e713. doi: 10.1093/cid/ciaa391.
2019
Tractable targets for meropenem-sparing antimicrobial stewardship interventions. Clark D Russell, Ian F Laurenson, Morgan H Evans, Claire L Mackintosh. JAC-Antimicrobial Resistance, Volume 1, Issue 2, September 2019, dlz042, https://doi.org/10.1093/jacamr/dlz042
A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. Charlier C, Wolf FI, Vlieghe E, Planquette B, Damme PV, Gaetano K, Buffet P, Henry B, Cevik M, Leen C, Laurenson I, Cameron H, Ogavu J, Nabankema E, Omona V, Valnaud P, Mackintosh C, Johannessen I, Geertruyden JV, Jeunne CL, Cauda R. Future Microbiol. 2019 Mar;14:369-372. doi: 10.2217/fmb-2019-0037
2018
Staphylococcus aureus endocarditis associated with injecting new psychoactive substances. Joshi SS, Henderson N, Griffith DJ, Henriksen PA, Denvir MA, Macsween KF, Mackintosh CL, Inverarity D. J R Coll Physicians Edinb. 2018 Dec;48(4):304-310. doi: 10.4997/JRCPE.2018.404.
2017
International infectious diseases teaching to undergraduate medical students: A successful European collaborative experience. Charlier C, Johannessen I, Mackintosh CL, Wilks D, Med Teach. 2017 Sep;39(9):981-986. doi: 10.1080/0142159X.2017.1332364.
2016
Diagnosis and features of hospital-acquired pneumonia: a retrospective cohort study. Russell CD, Koch O, Laurenson IF, O’Shea DT, Sutherland R, Mackintosh CL. J Hosp Infect. 2016 Mar;92(3):273-9. doi: 10.1016/j.jhin.2015.11.013.
Staphylococcus aureus bacteraemia associated with injected new psychoactive substances. Griffith DJ, Mackintosh CL, Inverarity D. Epidemiol Infect. 2016 Apr;144(6):1257-66. doi: 10.1017/S095026881500271X
2014
A granulomatous chronic disease. Stockdale AJ, Mackintosh CL, Roberston KE, Helgason KO. Am J Med. 2014 May;127(5):e5-6. doi: 10.1016/j.amjmed.2013.12.012
2013
Improving antimicrobial prescribing: implementation of an antimicrobial i.v.-to-oral switch policy. McCallum AD, Sutherland RK, Mackintosh CL. J R Coll Physicians Edinb. 2013;43(4):294-300. doi: 10.4997/JRCPE.2013.403.
2012
Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. Chan JA, Howell KB, Reiling L, Ataide R, Mackintosh CL, Fowkes FJ, Petter M, Chesson JM, Langer C, Warimwe GM, Duffy MF, Rogerson SJ, Bull PC, Cowman AF, Marsh K, Beeson JG. J Clin Invest. 2012 Sep;122(9):3227-38. doi: 10.1172/JCI62182.
2011
Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. Mackintosh CL, White HA, Seaton RA. J Antimicrob Chemother. 2011 Feb;66(2):408-15. doi: 10.1093/jac/dkq445
2010
Hospitalised adult patients with Suspected 2009 H1N1 Infection at Regional Infectious Diseases Units in Scotland–most had alternative final diagnoses. Ho A, Fox R, Seaton RA, MacConnachie A, Peters E, Mackintosh CL, Todd WT, Kennedy N, Dundas S, Gunson R. J Infect. 2010 Jan;60(1):83-5. doi: 10.1016/j.jinf.2009.11.001
2009
Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, Musyoki JN, Bull PC, Marsh K. Infect Immun. 2009 May;77(5):1917-23. doi: 10.1128/IAI.01358-08
2008
Acquisition of naturally occurring antibody responses to recombinant protein domains of Plasmodium falciparum erythrocyte membrane protein 1. Mackintosh CL, Christodoulou Z, Mwangi TW, Kortok M, Pinches R, Williams TN, Marsh K, Newbold CI. Malar J. 2008 Aug 16;7:155. doi: 10.1186/1475-2875-7-155
Failure to respond to the surface of Plasmodium falciparum infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Mackintosh CL, Mwangi T, Kinyanjui SM, Mosobo M, Pinches R, Williams TN, Newbold CI, Marsh K. Int J Parasitol. 2008 Oct;38(12):1445-54. doi: 10.1016/j.ijpara.2008.03.009
2004
Clinical features and pathogenesis of severe malaria. Mackintosh CL, Beeson JG, Marsh K. Trends Parasitol. 2004 Dec;20(12):597-603. doi: 10.1016/j.pt.2004.09.006.
1997
Elimination of motor nerve terminals in neonatal mice expressing a gene for slow wallerian degeneration (C57Bl/Wlds). Parson SH, Mackintosh CL, Ribchester RR. Eur J Neurosci. 1997 Aug;9(8):1586-92. doi: 10.1111/j.1460-9568.1997.tb01516.x.
Dr Kate Templeton
Position:
Consultant Clinical Scientist, RIE and Honorary Senior Lecturer in Medical Microbiology
Research Interests:
Molecular Epidemiology
Paediatric Medicine
Obstetrics
Critical Care
Blood Borne Viruses
Sexual Health
Background:
Dr. Templeton did her undergraduate study at Edinburgh University, doing a final year honours project with Dr Maurice Gallagher. Thereafter she trained as a clinical scientist at Barts and the London, and worked towards FRCPath examination under supervision of Professor Don Jeffries. In 2000 she moved to Leiden University Medical Centre to obtain her PhD and carried out further postgraduate study under supervision of Professor Herman Goossens and Professor Louis Kroes. She returned to Edinburgh in 2005 and now delivers the clinical virology service in Edinburgh alongside three medical consultants.
Her particular interests and clinical collaborations are in paediatric medicine, obstetrics, critical care, blood borne viruses and sexual health.
Her main focus is on clinically useful molecular diagnostics and molecular epidemiology and has several current research grants as well as collaborations with diagnostic companies on developing new molecular assays for diagnosis across pathology. She has previously worked on EU project in Leiden the Netherlands for 5 years. In 2006 she was awarded the Abbott Diagnostic prize from European Society for Virology (ESCV) for her original contributions in the area of viral diagnosis.
Outside professional life, she is former international rower and was a member of the British Olympic team in 1995-6.
Key Publications:
2011
Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient. McAdam PR, Holmes A, Templeton KE, Fitzgerald JR. PLoS One. 2011;6:e24301. Epub 2011 Sep 2.
Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model. Gaunt ER, Harvala H, McIntyre C, Templeton KE, Simmonds P. J Clin Virol. 2011;52:215-21.
Influenza A(H1N1)2009 antibody seroprevalence in Scotland following the 2010/11 influenza season. Adamson WE, McGregor EC, Kavanagh K, McMenamin J, …Templeton KE,… Carman WF. Euro Surveill. 2011;16:19871.
Rapid simultaneous detection of enterovirus and parechovirus RNAs in clinical samples by one-step real-time reverse transcription-PCR assay. Bennett S, Harvala H, Witteveldt J, McWilliam Leitch EC,…Templeton K,… Simmonds P.J Clin Microbiol. 2011 ;49:2620-4.
Comparison of human parechovirus and enterovirus detection frequencies in cerebrospinal fluid samples collected over a 5-year period in edinburgh: HPeV type 3 identified as the most common picornavirus type. Harvala H, McLeish N, Kondracka J, McIntyre CL, McWilliam Leitch EC, Templeton K, Simmonds P. J Med Virol. 2011;83:889-96. doi: 10.1002/jmv.22023.
Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus. Gaunt ER, Jansen RR, Poovorawan Y, Templeton KE, Toms GL, Simmonds P. PLoS One. 2011 Mar 1;6(3):e17427.
Rapid testing for respiratory syncytial virus in a paediatric emergency department: benefits for infection control and bed management. Mills JM, Harper J, Broomfield D, Templeton KE. J Hosp Infect. 2011;77(3):248-51. Epub 2011 Jan 31.
Real-time evaluation of an optimized real-time PCR assay versus Brilliance chromogenic MRSA agar for the detection of meticillin-resistant Staphylococcus aureus from clinical specimens. Danial J, Noel M, Templeton KE, Cameron F, Mathewson F, Smith M, Cepeda JA. J Med Microbiol. 2011 Mar;60(Pt 3):323-8.
Dr Rebecca K Sutherland
MRCP FRCPath FRCP (Edin)
Position:
Consultant in Infectious Diseases, NHS Lothian & Honorary Senior Clinical Lecturer, Edinburgh University
Research Interests:
Optimising Antimicrobial Therapy for Clinical Infection
Allergy and Infection
Vaccination
HIV Therapeutics and Standards of Care
Projects/ grants:
PI for Oral vs IV therapy for bone and joint infection (OvIVA)
PI for Oxford COVID-19 vaccine study (COV002 and COV009)
PI IONOE study
PI for RIO study
Background:
Dr Rebecca Sutherland was appointed as Consultant in Infectious Diseases in 2012 at the Western General Hospital, NHS Lothian. Prior to moving back to Edinburgh, Dr Sutherland trained in Infectious Diseases and Microbiology in Oxford and was a research fellow in vaccine immunology in the Weatherall Institute of Molecular Medicine.
Key Publications:
2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS_CoV-2 VOC 202012/01 (B.1.1.7) Katherine Emary, Golubchik Y, Aley P, Ariani C, …, Rebecca K Sutherland, …, Alexander D Douglas*, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Andrew J Pollard*, on behalf of the Oxford COVID Vaccine Trial Group† Lancet Mar 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Merryn Voysey*, Sue Ann Costa Clemens*, Shabir A Madhi*, Lily Y Weckx*, Pedro M Folegatti*, …, Rebecca K Sutherland, …, Alexander D Douglas*, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Andrew J Pollard*, on behalf of the Oxford COVID Vaccine Trial Group† Lancet Feb 2021
Expect the unexpected- Implications for next phase of COVID-19 response Clifford S, Cevik C, Campbell R, O’Shea D, Sutherland R. Infect Prev Pract. 2021 Jun;3(2):100118. doi: 10.1016/j.infpip.2021.100118.
2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of randomised controlled trials in Brazil, South Africa and the United Kingdom Merryn Voysey; Sue Ann Costa Clemens; Shabir A Madhi; Lily Yin Weckx;…; Rebecca K Sutherland;…; Andrew J Pollard, Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1.
Outcomes, Microbiology and Antimicrobial Usage in Pressure Ulcer-Related Pelvic Osteomyelitis: Messages for Clinical Practice. Russell CD, Tsang STJ, Simpson AHRW, Sutherland RK. J Bone Jt Infect 2020; 5(2):67-75.
British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of gastrointestinal opportunistic infections 2020.Chadwick DR, Sutherland RK, Raffe S et al. HIV Med. 2020; 21 Suppl 5; 1-19
An Algorithm for safe de-labelling of antibiotic allergy in adult hospital inpatients Sneddon, Jacqueline; Cooper, Lesley; Ritchie, Neil; Steele, Cathal; Spears, Mark, McEwen Jo; Dempsey,Zoey; Sutherland, Rebecca; Khatamzas, Elham; Seaton,R. Clinical and Experimental Allergy. Mar 2021. 2021 Sep;51(9):1229-1232. doi: 10.1111/cea.13878.
The index case of SARS-CoV-2 in Scotland. Hill KJ, Russell CD, Clifford S, Templeton K, Mackintosh CL, Koch O, Sutherland RK. J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.022.
A retrospective review and multi-specialty, evidence-based guideline for the management of Necrotising Otitis Externa Hopkins M, Baring D, Macsween K, Henderson N, Baring D, Sutherland R . J Laryngol Otol. 2020 Jun;134(6):487-492. doi: 10.1017/S0022215120001061
2019
Oral versus Intravenous Antibiotics for Bone and Joint Infection. Ho-Kwong Li, Ines Rombach, Rhea Zambellas, A. Sarah Walker, …, Rebecca K. Sutherland, …and Matthew Scarborough et al for the OVIVA Trial Collaborators N Engl J Med. 2019 Jan 31;380(5):425-436. doi: 10.1056/NEJMoa1710926.
2017
Nocardia and Actinomyces. Henderson NM, Sutherland RK. Medicine Infections Chapter. Part 3 of 3. Vol 45:12 Dec 2017
2016
What you need to know about Whipple’s disease. Tsarfati EM, Sutherland R. British Journal of Hospital Medicine. 2016
2015
Diagnosis and features of hospital acquired pneumonia: a retrospective cohort study CD Russell, O Koch, IF Laurenson, DT O’Shea, R Sutherland, CL Mackintosh. Journal Hospital Infection. 2015 1-7
Elevation of the JVP in constrictive pericarditis. Sutherland R, Russell KV, Trivedi P, Richard W Smith, Conlon CP. QJM. 2015 Oct;108(10):846. doi: 10.1093/qjmed/hcv048. Epub 2015 Feb 19
2014
A constricting differential- a case of severe anaemia, weight loss and pericarditis due to Tropheryma whipplei infection. Sutherland R, Russell KV, Trivedi P, Warren B, Richard W Smith, Conlon CP. QJM. 2014 Nov;107(11):927-9. doi: 10.1093/qjmed/hcs041.
2013
Improving antimicrobial prescribing: implementation of an antimicrobial iv-to-oral switch policy. Mccallum A, Sutherland R, Mackintosh C. J R Coll Physicians. Edinb. 2013;43(4):294-300. doi: 10.4997/JRCPE.2013.403.
HIV-associated late seminal vesicle “BCGosis” following intravesical bacille Calmette-Guerin therapy. Eyre DW, Mankia K, Sutherland R, Turner G, Conlon C. 2013. J Clin Urol. 6:20–21.
2008
Lessons from IAVI-006, a phase 1 clinical trail to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Guimaraes-Walker A, Mackie N, McCormack S, Hanke T, …, Kay R,…, Fast P; IAVI-006 Study Group Vaccine. 2008 Dec 2;26(51):66671-7. doi: 10.1016/j.vaccine.2008.09.016.
2006
Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. Sutherland R, Yang H, Scriba TJ, Ondondo B, …, Dorrell L. AIDS. 2006 Apr 4;20(6):821-9. doi: 10.1097/01.aids.0000218545.31716.a4.
2005
A new dawn for antiretrovirals. Sutherland R. BMJ .2005; 330:371
2003
Vaccine for specific targets: HIV. Kay R, Wee E.G-T, McMichael AJ. Chapter in Novel Vaccine Strategies edited by Stefan HE Kaufmann, p505-528, published 2006
Dr Meghan R Perry
MBChB, DTM&H, PhD, FRCP(ID)
Position:
Consultant in Infectious Diseases & Honorary Senior Clinical Lecturer
Research Interests:
Antimicrobial Resistance
Urinary Tract Infections
COVID-19
Projects/ grants:
Collaboration with DataLoch and EaveII (UoE) re COVID-19 and deprivation
Collaboration with Epigroup UoE on metagenomics of sewage as surveillance tool for AMR
“The Mould that Changed the World” musical AMR public engagement project.
Background:
Following obtaining an MBChB from Edinburgh University in 2002 Dr Perry pursued core medical training with a specific interest in infectious diseases working in hospitals in London and Edinburgh and obtaining a Diploma in Tropical Medicine and Hygiene in 2006. During her specialist training post in Edinburgh in Infectious Diseases she wrote a PhD on pathogen resistance looking the interaction between arsenic exposure and resistance to antimony in the parasite Leishmania. She was appointed consultant in Infectious Diseases in 2018 and continues to pursue research interests as above.
Publications:
2021
Segmentation and shielding of the most vulnerable members of the population as elements of an exit strategy from COVID-19 lockdown. van Bunnik BAD, Morgan ALK, Bessell PR, Calder-Gerver G, …, Perry MR, …, Woolhouse MEJ. Philos Trans R Soc Lond B Biol Sci. 2021 doi: 10.1098/rstb.2020.0275.
Diagnostic performance of the combine nasal and throat swab in patients admitted to hospital with suspected COVID-19 Lee KK, Doudesis D, Ross D, Bularga A, …, Perry MR, Nicholas L Mills, DataLoch COVID-19 Collaboration. BMC Infect Dis 2021 doi: 10.1186/s12879-021-05976-1.
Epidemiology of and risk factors for mortality due to carbapenemase-producing organisms (CPO) in healthcare facilities Zhao S, Kennedy S, Perry MR, Wilson J,…, Lockhart M Journal of Hospital Infection 2021 110: 184-193
2020
Risk Factors for the Presence of Carbapenem-Resistant Organisms (CROs) in Carbapenemase-producing organisms in Scotland: risk factors associated with infection and colonisation among hospitalised patients Zhao S , Perry MR, Kennedy S, Wilson J, …, Woolhouse MEJ Infect Control Hosp Epidemiology 2020 Dec 22;1-10. doi:10.1017/ice.2020.1351.
‘The Mould that Changed the World’: Quantitative and Qualitative Evaluation of Children’s Knowledge and Intention for Behavioural Change following Participation in an Antimicrobial Resistance Musical Hall J, Jones L, Robertson G, Hiley R, Nathwani D, Perry MR. PLoS ONE 29 Oct 2020, https://doi.org/10.1371/journal.pone.0240471
Oxygen provision in Sub-Saharn Africa to fight COVID-19 Stein, F., Perry, M.R., Banda, G., Woolhouse, M., Mutapi, F.
BMJ Global Health. 30 Apr 2020
Staff and patient perceptions of a community urinary catheter service. Freya Oswald, Ellen Young, Fiona Denison, Rosalind Allen, Meghan R Perry. Int J Urol Nurs. 2020 Jul; 14(2): 83–91.
Exposure to pigs and health outcomes in hospitalised infectious disease patients in Vietnam Gail Robertson, Meghan R. Perry, Phat Voong Vinh, Dung Tran Thi Ngoc, …, Mark Woolhouse, on behalf of the VIZIONS consortium. Ecohealth 2020 Mar;17(1):28-40
2016
Global disease burden due to antibiotic resistance – state of the evidence Mark Woolhouse, Catriona Waugh, Meghan R. Perry, Harish Nair. J Glob Health 2016 Jun;6(1):010306
2015
Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India. A retrospective cohort study. Meghan R. Perry, Vijay K Prajapati, Joris Menten, Andrea Raab, …, Albert Picado. PLoS Negl Trop Dis 2015 Mar 2;9(3):e0003518.
2013
Chronic arsenic exposure and clinical resistance to antimonial drugs in visceral leishmaniasis: proof of concept in mouse model. Meghan R. Perry, Susan Wyllie, Andrea Raab, Joerg Feldmann, Alan H. Fairlamb
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19932-7
Chronic arsenic exposure and clinical resistance to antimonial drugs in visceral leishmaniasis: proof of concept in mouse model. Meghan R. Perry, Susan Wyllie, Andrea Raab, Joerg Feldmann, Alan H. Fairlamb
Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19932-7
The R enantiomer of the anti-tubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis
Stephen Patterson, Susan Wyllie, Laste Stojanovski, Meghan R. Perry,…, and Alan H. Fairlamb. Antimicrob Agents Chemother. 2013 Oct;57(10):4699-706
2012
HIV testing – getting the message across: a survey of knowledge, attitudes and practice amongst non-HIV specialist physicians Ewan Hunter*, Meghan R. Perry*, Clifford Leen, Nikhil Premchand
Postgrad Med J. 2012 Feb;88(1036):59-65. *Joint first author
2011
Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian Subcontinent? Meghan R. Perry, Susan Wyllie, Vijay Kumar Prajapati, Joerg Feldmann, …, Alan H. Fairlamb PLoS Negl Trop Dis. 2011 Sep;5(9):e1227
2006
Cytokine Storm in a Phase 1 Trial of the Anti CD-28 Monoclonal Antibody Ganesh Suntharalingam, Meghan R Perry, Stephen Ward, Stephen J. Brett, …, Nicki Panoskaltsis N Engl J Med. 2006 Sep 7;355(10) :1018-28.
Prof David Dockrell
MD
Position:
Chair of Infection Medicine-University of Edinburgh, Head of Centre- Centre for Inflammation Research/Institute of Regeneration and Repair, Co-director Edinburgh Infectious Diseases
Research Interests:
Innate immune responses to infection and regulation of inflammation
Microbicidal mechanisms against bacterial infection
Host based strategies to combat antimicrobial resistence
One Health approaches to infectious diseases
HIV medicine and infections in immunocompromised hosts
Projects/ grants:
The SHIELD Consortium (The Universities of SHeffield, Edinburgh, BIrmingham and Newcastle Led Partnership to Develop Host Defence Therapeutics) Optimising Innate Host Defence to Combat Antimicrobial Resistance PI Dockrell December 2016-23 £ 3,592,676 MR/N02995X/1
Medical Research Foundation National PhD Training Programme in Antimicrobial Resistance PI M. Avison (Co-I A. Bailey, D. Crook, D. Dockrell, C. Dowson, M. Holmes, A. Singer, D. Stekel and C. Walti) Sept 2017- Dec 2022. £2, 451,007. MRF-145-0004-TPG-AVISO
CSO Scotland Covid UoE Portfolio (lead) COV/EDI/20/4, 10, 11, 12, 13, 16, 17, 18) 2020-21 £603,500
UKRI-MRC Programme Grant (MICA) Mitochondrial dysfunction in macrophages and impaired bacterial clearance in chronic obstructive pulmonary disease (COPD) PI D Dockrell December 2022-27 £1,938,359 MR/W028506/1
https://www.ed.ac.uk/inflammation-research
https://www.ed.ac.uk/inflammation-research/people/principal-investigators/professor-david-dockrell
Background:
David’s research interest has focused on pathogenesis of infectious disease and mechanism of susceptibility. He has in particular promoted studies to identify mechanism that can be exploited as host based therapy to combat antimicrobial resistance and severe viral infections. David is part of the management group for the national doctoral training programme in antimicrobial resistance. He helps co-ordinate infection activities through the university through his roles in the Centre for Inflammation Research and Edinburgh Infectious Diseases
Key Publications:
2023
NRF2 Activation Reprogrammes Defects in Oxidative Metabolism to Restore Macrophage Function in COPD. E.M. Ryan, P. Sadiku, P. Coelho, E.R. Watts, A. Zhang, A.J.M. Howden, M.A. Sanchez-Garcia, M. Bewley, J. Cole, B.J. McHugh, W. Vermaelen, B. Ghesquiere, P. Carmeliet, G. Rodriguez Blanco, A. Von Kriegsheim, Y. Sanchez, W. Rumsey, J.F. Callahan, G. Cooper, N. Parkinson, K. Baillie, D.A. Cantrell, J. McCafferty, G. Choudhury, D. Singh, D.H. Dockrell, M.K.B. Whyte, S.R. Walmsley. American Journal of Respiratory and Critical Care Medicine. 2023 Feb 1. doi: 10.1164/rccm.202203-0482OC. Online ahead of print. PMID: 36724365
2022
Phagosomal acidification is required to kill Streptococcus pneumoniae in a zebrafish model. T.K. Prajsnar, B. Michno, N. Pooranachandran, A.K. Fenton, T.J. Mitchell, D.H. Dockrell, S. A. Renshaw. Cellular Microbiology. 2022 10.1155/2022/9429516
The prevalence of hypoxemia in children with pneumonia in low-income and middle-income countries: a systematic review and meta-analysis. A.E. Rahman, A.T. Hossain, H. Nair, M. J. Chisti, D. Dockrell, S. El Arifeen, H. Campbell. The Lancet Global Health 2022: 10; e348-359
2021
Pneumolysin is responsible for differential gene expression and modifications in the epigenetic landscape of primary monocyte derived macrophages. J. Cole, A. Angyal, R. D.Emes, T.J. Mitchell, M.J. Dickman, D.H. Dockrell. Frontiers Immunology 2021 12:573266. doi: 10.3389/fimmu.2021.573266
Neutrophil HIF-1α stabilisation is augmented by mitochondrial ROS produced via the glycerol 3-phosphate shuttle. J.A. Willson, S. Arienti, P. Sadiku, L. Reyes, …,, D.H. Dockrell, …, S. Walmsley. Blood. In press doi: 10.1182/blood.2021011010
The effect of live attenuated influenza vaccine on pneumococcal colonization densities among children aged 24-59 months in the Gambia – A phase IV, open label, randomized controlled trial. C. Penoa, E.P. Armitage, M. Clerca, C.L. Balcazara, Y.J. Jagneb, S. Drammehb, S. Jarjub, H. Sallahb, E. Senghoreb, B.B. Lindsey, J. Camara, S. Bah, N.I. Mohammed, D.H. Dockrell, B. Kampmann, E. Clarke, D. Bogaert & T.I. de Silva. The Lancet Microbe. 2021: 2; 2656-65
2020
Genome-wide CRISPR screen Identifies Host Dependency Factors for Influenza A Virus Infection. B. Li, S. Clohisey, B. S. Chia, B. Wang, …, D. Dockrell,…, and N. Hacohen. Nature Communications 2020: 11; 164
2019
Alveolar macrophage apoptosis-associated bacterial killing helps prevent murine pneumonia. J.A. Preston, M.A. Bewley, H.M. Marriott, A.M. Houghton, M. Mohasin, J. Jubrail, L. Morris, Y.L. Stephenson, S. Cross, D.R. Greaves, R.W. Craig, N. van Rooijen, C.D. Bingle, R.C. Read, T.J. Mitchell, M.K.B. Whyte, S.D. Shapiro and D. H. Dockrell. American Journal of Respiratory and Critical Care Medicine 2019: 200; 84-97 doi: 10.1164/rccm.201804-0646OC.PMID 30649895
2018
Opsonic phagocytosis in chronic obstructive pulmonary disease is enhanced by Nrf2 agonists. M.A. Bewley, R.C. Budd, E. Ryan, J. Cole,… and D. H. Dockrell. American Journal of Respiratory and Critical Care Medicine 2018: 198; 739-50 doi10/1164/rccm.201705-0903O
HIV gp120 in lungs of ART-treated individuals impairs alveolar macrophage responses to pneumococci. P.J. Collini, M.A. Bewley, M. Mohasin, H.M. Marriott,… and D. H. Dockrell. American Journal of Respiratory and Critical Care Medicine 2018: 197; 1604-15
Dr Matt Adam
MB BChir MA(Cantab) MRCP(UK) DTMH RAF
Position:
Consultant in Infectious Diseases & General Medicine
Research Interests:
Infectious Diseases
COVID-19
Aviation medicine
Projects/ grants:
Local PI for AZD2816 AstraZeneca COVID-19 Vaccine trial
Background:
Dr Matt Adam was appointed as a consultant in Infectious Diseases in 2020. In addition to his work with RIDU, he works for the Royal Air Force with a main role in aeromedical evacuation, and lectures on infectious diseases and aviation for professional courses run by King’s College, London.
Key Publications:
2022
Ernsting’s Aviation and Space Medicine. (Chapter Author). Rainford, D, and David P. Gradwell. Occup Med (Lond), 2022 (in press)
All Publications:
2021
2020-2021 Multiple papers as collaborator with Oxford COVID Vaccine Trial Group and RECOVERY Collaborative Group.
2019
Handbook of Aviation and Space Medicine (Chapter Author) Edited by Nicholas Green, Steven Gaydos, Ewan Hutchison, Edward Nicol. Occupational Medicine, Volume 70, Issue 4, June 2020, https://doi.org/10.1093/occmed/kqaa020
Aeromedical Transfer of Patients with Viral Hemorrhagic Fever. Nicol ED, Mepham S, Naylor J, Mollan I, Adam M, …, Jacobs M. Emerg Infect Dis. 2019 Jan;25(1):5-14. doi: 10.3201/eid2501.180662.
2018
Enhanced case management can be delivered for patients with EVD in Africa: Experience from a UK military Ebola treatment centre in Sierra Leone. Dickson SJ, Clay KA, Adam M, …, Fletcher TE. J Infect. 2018 Apr;76(4):383-392. doi: 10.1016/j.jinf.2017.12.006.
2017
Trial Evaluating Ambulatory Therapy of Travelers’ Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide. Riddle MS, Connor P, Fraser J, Porter CK, Swierczewski B, Hutley EJ, Danboise B, Simons MP, Hulseberg C, Lalani T, Gutierrez RL, Tribble DR; TrEAT TD Study Team. Clin Infect Dis. 2017 Nov 29;65(12):2008-2017. doi: 10.1093/cid/cix693.
2016
Transferring patients with Ebola by land and air: the British military experience. Ewington I, Nicol E, Adam M, Cox AT, Green AD. J R Army Med Corps. 2016 Jun;162(3):217-21. doi: 10.1136/jramc-2016-000623.
2015
Use of an ultraviolet tracer in simulation training for the clinical management of Ebola virus disease. J Hosp Infect. Clay KA, O’Shea MK, Fletcher T, Moore AJ, …, Adam M, …, Gibson C. 2015 Nov;91(3):275-7. doi: 10.1016/j.jhin.2015.07.006.
2014
Venous thromboembolism: reducing the risk in a Role 3 setting. Craig DG, Adam MG, Proffitt A, Parsons I, Tai NR, d’Arcy JL. J R Army Med Corps. 2014 Dec;160(4):304-9. doi: 10.1136/jramc-2013-000199.
Dr Simon Dewar
FRCPath, PhD, MBChB, BMSc (Hons)
Position:
Consultant in Medical Microbiology, Clinical Lead Antimicrobial Management Team, Honorary Lecturer University of Edinburgh
Email:
simon.dewar@nhslothian.scot.nhs.uk
Research Interests:
Antimicrobial Stewardship
Drug Discovery
Infection Prevention and Control
Projects/ grants:
Lothian PI for TIDE: Trial of De-colonisation
A multi-centre, randomised controlled, non-inferiority and cost effectiveness trial comparing Polyhexanide and Chlorhexidine with Neomycin to Mupirocin for nasal methicillin resistant Staphylococcus aureus (MRSA) decolonisation amongst adult hospital in-patients
Background:
Dr Dewar did his undergraduate medical studies at the University of Dundee, also attaining a first class BMSc in Neurosciences. He completed his specialist training in medical microbiology in the North East of England and during this time undertook a PhD, University of Dundee, focusing on the folate pathway and drug discovery in African trypanosomiasis. He has worked as a microbiology consultant in NHS Lothian since 2019 and is currently the clinical lead for Lothian’s antimicrobial management team. His particular interests are antimicrobial stewardship, drug discovery and infection prevention and control.
Key Publications:
2019
Dewar S, Vass D, Mackenzie F, Parcell BJ (2019) Point-of-care testing by healthcare workers for detection of meticillin-resistant Staphylococcus aureus, Clostridioides difficile, and norovirus. Journal of Hospital Infection 103, 444-53
2016
Dewar S, Sienkiewicz N, Ong HB, Wall RJ, Horn D, Fairlamb AH (2016). The Role of Folate Transport in Antifolate Drug Action in Trypanosoma brucei. Journal of Biological Chemistry 291, 24768-24778.
2014
Dewar S, Reed LC, Koerner RJ (2014). Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. Journal of Antimicrobial Chemotherapy 69, 303-308.
All Publications:
2022
Kelly J, Tysall L, Dewar S (2022) Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm) Journal of Antimicrobial Chemotherapy 77 1432-1435
2021
Ahmed W, Dewar S, Williams R, Stansby G, Harris K, Weiand D (2021) Lawsonella clevelandensis is a Rare Cause of Infected Chronic Contained Rupture of Abdominal Aortic Aneurysm. Access Microbiology 3, 000183
2019
Dewar S, Vass D, Mackenzie F, Parcell BJ (2019) Point-of-care testing by healthcare workers for detection of meticillin-resistant Staphylococcus aureus, Clostridioides difficile, and norovirus. Journal of Hospital Infection 103, 444-53.
2016
Dewar S, Sienkiewicz N, Ong HB, Wall RJ, Horn D, Fairlamb AH (2016). The Role of Folate Transport in Antifolate Drug Action in Trypanosoma brucei. Journal of Biological Chemistry 291, 24768-24778.
Gibson MW, Dewar S, Ong HB, Sienkiewicz N, Fairlamb AH (2016). Trypanosoma brucei DHFR-TS Revisited: Characterisation of a Bifunctional and Highly Unstable Recombinant Dihydrofolate Reductase-Thymidylate Synthase. PLoS Neglected Tropical Diseases 10, e0004714.
2015
Dewar S, Weir-McCall JR, Batchelor L, Cole S, Parcell BJ (2015). Bacillus Anthracis Meningitis During an Outbreak of Injectional Anthrax, Scotland, UK. Clinical Microbiology and Infection 21, e49-50.
2014
Dewar S, Reed LC, Koerner RJ (2014). Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. Journal of Antimicrobial Chemotherapy 69, 303-308.
2013
Dewar S, Bignardi GE, Settle C (2013). Increase in reported Clostridium difficile cases as unintended consequence of enhanced norovirus testing. Journal of Hospital Infection 85, 240-241.
2012
Macaskill EJ, Dewar S, Purdie CA, Brauer K, Baker L, and Brown DC (2012). Sentinel node biopsy in breast cancer has a greater node positivity rate than axillary node sample: results from a retrospective analysis. European Journal of Surgical Oncology 38, 662-669.
Dr Ian Laurenson
Position:
Consultant Microbiologist & Director of the Scottish Mycobacteria Reference Laboratory, Royal Infirmary of Edinburgh
Research Interests:
Mycobacteria
Non-tuberculous Mycobacterial Infection Epidemiology
Mycobacterial Diagnostics
Critical Care Collaborations.
Projects/Grants:
CRyPTIC TB Comprehensive Resistance Prediction for Tuberculosis: an International Consortium
Wellcome Trust Digital Technologies Innovator Award. Sequencing Pathogen Pipeline Platform (SP3) – extended to 2021 due to Covid 19 pandemic.
Background:
Dr Ian Laurenson is a Consultant Medical Microbiologist and Honorary Clinical Reader at the University of Edinburgh as well as until recently Head of Speciality and Clinical Lead for Microbiology and Virology at NHS Lothian.
Dr Laurenson trained and worked in medicine, infectious diseases and medical microbiology in Cambridge, Edinburgh, London, Papua New Guinea and Fife. His current roles are diverse including Directing the Scottish Mycobacteria Reference Laboratory and advising on mycobacterial infection, caring for patients with infection in critical care and solid organ transplantation, and managing infection control and antimicrobial stewardship. He also contributes to both undergraduate and postgraduate teaching and research. He was an author on the 2017 British Thoracic Society (BTS) NTM PD guidelines.
Recent Publications:
2024
Considering best practice standards for routine whole-genome sequencing for TB care and control Denholm JT, de Vries G, Anthony R, Robinson E, Backx M, Laurenson IF, Seagar AL, Modestil H, Trieu L, Meissner JS, Ng DHL, Tay JY, Lin HH, Lee R, Sintchenko V, Marais BJ, Donnan EJ. IJTLD Open. 2024 Oct 1;1(10):431-436. doi: 10.5588/ijtldopen.24.0320.
2021
False detection of rifampicin resistance using Xpert® MTB/RIF Ultra assay due to an A451V mutation in Mycobacterium tuberculosis. Fitzgibbon MM, Roycroft E, Sheehan G, Mc Laughlin AM,… Laurenson IF,… Rogers TR. JAC Antimicrob Resist. 2021 Aug 11;3(3):dlab101. doi: 10.1093/jacamr/dlab101.
Investigation of two cases of Mycobacterium chelonae infection in haemato-oncology patients using whole-genome sequencing and a potential link to the hospital water supply. Inkster T, Peters C, Seagar AL, Holden MTG, Laurenson IF. J Hosp Infect. 2021 Aug;114:111-116. doi: 10.1016/j.jhin.2021.04.028. Epub 2021 May 1. PMID: 33945838.
Sensitivity of RT-PCR testing of upper respiratory tract samples for SARS-CoV-2 in hospitalised patients: a retrospective cohort study. Williams TC, Wastnedge E, McAllister G, Bhatia R,…Laurenson I,… Templeton K. Wellcome Open Research 2020, 5:254
2020
A Subgroup of Patients With Hospital-acquired Pneumonia Do Not Require Broad-spectrum Gram-negative Antimicrobial Coverage.Clark D Russell, Ed Whittaker, Dominic P Dee, Eilidh Farquhar, …Ian F Laurenson,… Claire L Mackintosh, Muge Cevik. Clin Infect Dis. 2020 Dec 17;71(10):e710-e713. doi: 10.1093/cid/ciaa391
Ventilator-associated pneumonia surveillance using two methods. Craven TH, Wojcik G, McCoubrey J, Brooks O,… Laurenson IF,…Walsh TS. Hosp Infect. 2020 Apr;104(4):522-528. doi: 10.1016/j.jhin.2020.01.020. Epub 2020 Feb 5. PMID: 32035121.
2019
Tractable targets for meropenem-sparing antimicrobial stewardship interventions. Clark D Russell, Ian F Laurenson, Morgan H Evans, Claire L Mackintosh. JAC Antimicrob Resist. 2019 Sep 6;1(2):dlz042. doi: 10.1093/jacamr/dlz042
Lessons learned from a pneumocystis pneumonia outbreak at a Scottish Transplant Centre. A Mclarey, P Phelan, D. O’Shea, L Henderson, R Gunson, IF Laurenson. J Hosp Infect. 2019 Jul;102(3):311-316. doi: 10.1016/j.jhin.2019.02.013. Epub 2019 Feb 23.
2017
Three year evaluation of Xpert MTB/RIF in a low prevalence tuberculosis setting: A Scottish perspective. Parcell BJ, Jarchow-MacDonald AA, Seagar AL, Laurenson IF, Prescott GJ, Lockhart M. J Infect. 2017 May;74(5):466-472. doi: 10.1016/j.jinf.2017.02.005. Epub 2017 Feb 22.
2016
True rifampicin resistance missed by the MGIT: prevalence of this pheno/genotype in the UK and Ireland after 18 month surveillance. Gonzalo, Ximena; Claxton, Pauline; Brown, Tim; Montgomery, Lorraine; Fitzgibbon, MM; Laurenson, Ian; Drobniewski, Francis. Clin Microbiol Infect. 2017 Apr;23(4):260-263. doi: 10.1016/j.cmi.2016.11.015. Epub 2016 Nov 27. PMID: 27903459.
Pulmonary Mycobacterium marinum infection: ‘fish tank granuloma’ of the lung. Velu PP, Fernandes SE, Laurenson IF, Noble DD. Scott Med J. 2016 Nov;61(4):203-206. doi: 10.1177/0036933016680161. Epub 2016 Nov 21. PMID: 27872397.
Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I,… Laurenson I,… Floto RA. Science. 2016 Nov 11;354(6313):751-757. doi: 10.1126/science.aaf8156. PMID: 27846606; PMCID: PMC5142603.
Dr Daire O’Shea
Position:
Consultant Physician in Infectious Diseases
Research Interests:
Infection in Immunocompromised Hosts
Transplant Infectious Diseases
Bloodborne Virus Infection (HIV/Viral Hepatitis)
Background:
Dáire O’Shea is a Consultant Physician in Infectious Diseases in Edinburgh and an Honorary Clinical Senior Lecturer with University of Edinburgh. He is a graduate of Trinity College Dublin Medical School, and undertook Internal Medicine and Specialist Infectious Diseases Training in Ireland following by a Transplant Infectious Diseases Fellowship with the Alberta Transplant Institute in Canada. He was appointed to the ID Academic Faculty of the University of Alberta in 2013, prior to taking up his current position in 2014. Subspecialist interests include infection in immunocompromised hosts, in particular Transplant Infectious Diseases, and bloodborne virus infection (viral hepatitis/HIV). Research interests focus on immunopathogenesis and immune determinants of infection outcomes.
Key Publications:
2021
Expect the unexpected – Implications for next phase of COVID-19 response. Clifford S, Cevik M, Campbell R, O’Shea D, Sutherland RK. Infect Prev Pract 2021 Jun;3(2):100118. doi: 10.1016/j.infpip.2021.100118.
2014
The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Egli A, Santer DM, O’Shea D, Tyrrell D, Houghton M Emerg Microbes Infect. 2014 Jul; 3(7): e51.
IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. Egli A, Santer DM, O’Shea D, Barakat K, …, Kumar D PLoS Pathog 2014 Dec 11;10(12):e1004556.
2013
Life-Threatening Infection in Transplant Recipients. O’Shea DT , Humar A. Crit Care Clin 2013 Oct;29(4):953-73
Amy Shepherd
BSc MSc
Position:
Lead Research Nurse
Research Interests:
Infectious diseases
Clinical Trials
Background:
After graduating from Stirling University in 2008 with a BSc in Adult nursing, Amy worked as a Staff Nurse within the Vascular Surgical department at NHS Forth Valley. In 2014 Amy began working to pursue a career as a Research Nurse, firstly within the Wellcome Trust at Edinburgh’s Western General Hospital, gaining experience in early phase clinical trials. Having developed an interest in Infectious Diseases following working on the OVIVA Study, Amy began working as a Senior Research nurse at the Regional Infectious Diseases Unit in Edinburgh in 2014. During her time there she has worked on a variety of studies both commercial and academic in clinical infection including HIV, Hepatitis, C diff and SARS COVID-19. Since 2016 Amy has been a Committee Member of the South East Scotland Research Ethics Committee, this role involves reviewing research applications and amendments for ethical opinion and approval. Amy most recently obtained a MSc in Clinical Trials from Edinburgh University & has since become the Lead Research Nurse of CIRG.
Publications:
2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Voysey M,Costa Clemens, Madhi SA, Weckx LY,…Oxford COVID Vaccine Trial Group…Lancet. 2021 Mar 6;397(10277):881-891
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Voysey M, Clemens SAC, Madhi SA, Weckx LY,…Oxford COVID Vaccine Trial Group…Lancet. 2021 Jan 9;397(10269):99-11
Susie Ferguson
BSc
Position:
Senior Research Nurse
Email:
Research Interests:
Infectious Diseases
Respiratory Medicine
Background:
After graduating with a BSc (Hons) in Biomedical Sciences and a Diploma in Adult Nursing, Susie started her career working as a staff nurse in Respiratory Medicine at the Royal Infirmary of Edinburgh. In 2012 she joined the Respiratory Research team as a Senior Research Nurse, responsible for the day to day running of commercial and academic studies. In 2015 she undertook a deployment to West Africa, working with a team from Oxford University on a clinical trial treatment for Ebola Virus Disease. After a temporary redeployment to the Infectious Diseases research team in 2019 to support the Covid-19 studies, Susie joined the team permanently in 2020.
Key Publications:
2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Voysey M,Costa Clemens, Madhi SA, Weckx LY,…Oxford COVID Vaccine Trial Group…Lancet. 2021 Mar 6;397(10277):881-891
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS_CoV-2 VOC 202012/01 (B.1.1.7) Katherine Emary, Golubchik Y, Aley P, Ariani C, …, Rebecca K Sutherland, …, Alexander D Douglas*, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Andrew J Pollard*, on behalf of the Oxford COVID Vaccine Trial Group† Lancet Mar 2021
2016
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single Arm Phase 2 Clinical Trial Dunning J, Sahr F….RAPIDE-TKM trial team PLoS Med 2016;13:e1001997
2014
18F-fluorodeoxyglucose (18-FDG) PET pulmonary imaging: comparative methodology in COPD patients Choudhury G, Fletcher A, Connell M, Clark T, Ferguson S, Rabinovich R, Weir N, Whitcher B, Kilty I, Vennart W, Van Beek E, MacNee W:18F-fluorodeoxyglucose (18-FDG) PET pulmonary imaging: comparative methodology in COPD patients. European Respiratory Journal. 2014
All Publications:
2014
HELP-COPD: A qualitative study of need in people with COPD Pinnock H, Kendall M, Buckingham S, Ferguson S, Sheikh A, Macnee W, White P, Worth A, Boyd K, Murray S:European Respiratory Journal. 2014 Sep:44(supp;58)
2013
HELPing people with very severe COPD: Feasibility study of a novel holistic intervention. Buckingham S, Kendall M, Ferguson S, Sheikh A, Murray S, Macnee W, White P, Worth A, Boyd K, Pinnock H European Respiratory Journal. 2013
Louise Sharp
BSc, BN
Position:
Senior Research Nurse
Email:
Research Interests:
Infectious Diseases
COVID-19
Background:
After graduating with a BSc (Hons) in Evolutionary Biology from the University of Edinburgh, Louise chose to pursue a career in nursing, graduating first in class at Edinburgh Napier University with a BN (Adult). Louise started her career working as a staff nurse in Respiratory Medicine at the Royal Infirmary of Edinburgh in 2018. To support COVID-19 research efforts, Louise accepted a short research secondment before returning to Respiratory Medicine as a deputy charge nurse. With her secondment having piqued her interest in research, she chose to pursue a career in research nursing and joined the CIRG in January 2022.
Anne Saunderson
BSc
Position:
Senior Research Nurse
Email:
Research Interests:
Infectious diseases
Fertility
Cardiology
Background:
Having trained as an RGN at North Lothian College, Edinburgh, fulfilling a staff nurse post and completing midwifery training at Foresterhill College, Aberdeen, Anne has spent a varied career working in the UK and overseas within the NHS, private, and charitable sector, before completing a Bsc in Nursing with Health Studies at Napier University. Anne’s research interest began in the ED at RIE in 2006, followed by many years in fertility research with Prof Anderson. In 2015 she undertook a deployment to West Africa, working with a team from Oxford University on a clinical trial treatment for Ebola Virus Disease. Going forward, Anne then worked with this team for Covid trials during the pandemic leading her to join the (then) newly set up Covid-19 Research Group. This joined the RIDU Research Team & thus Anne migrated to CIRG.
Key Publications:
2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS_CoV-2 VOC 202012/01 (B.1.1.7) Katherine Emary, Golubchik Y, Aley P, Ariani C, …, Rebecca K Sutherland, …, Alexander D Douglas*, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Andrew J Pollard*, on behalf of the Oxford COVID Vaccine Trial Group† Lancet Mar 2021
2016
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single Arm Phase 2 Clinical Trial. Dunning J, Sahr F….RAPIDE-TKM trial team PLoS Med 2016
2009
A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Gray AJ, Goodacre S, Newby DE, Masson MA, Sampson F, Dixon S, et al. Health Technol Assess 2009;13(33).
Connor Dalby
BSc, MSc
Position:
Clinical Trials Assistant
Email:
Research Interests:
Infectious Diseases
COVID-19
Alzheimer's Disease
Synaptic Memory
Background:
Connor graduated with a BSc in Psychology from Plymouth University in 2019. During his degree he completed a placement in clinical research, acting as a springboard for his career. Connor later completed a MSc in Molecular Neuroscience at The University of Bristol in 2020. After graduating, Connor worked with NHS Lothian as Associate Practitioner in Laboratory Medicine. He is currently a Clinical Trials Assistant within CIRG, providing data management and administrative support to trials of therapeutics and vaccines for COVID-19, HIV, Sexually Transmitted Infections, and other infectious diseases.
